Related Experiment Video
Updated: May 15, 2025
02:28
Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
Published on: March 1, 2024
313
Dementia Risk in Psoriasis Patients Treated with Biologics: A Propensity Score-matched Population-based Cohort Study
Jen A Barak Levitt1, Michael Ziv2
1Department of Dermatology, Emek Medical Center, Afula, Israel; Ruth and Bruce Rappaport Faculty of Medicine, Technion Institute of Technology, Haifa, Israel. Jen.Levitt.Barak@gmail.com.
Acta Dermato-Venereologica
|May 14, 2025
Summary
Biologic therapies for psoriasis, targeting tumor necrosis factor-alpha and interleukins, may significantly reduce dementia risk in older adults. This finding suggests potential neuroprotective benefits beyond skin health.
Area of Science:
- Dermatology
- Neurology
- Pharmacology
Background:
- Psoriasis treatments, particularly biologics, show potential neuroprotective effects.
- Translational research and animal models suggest a link between psoriasis therapies and reduced dementia risk.
Purpose of the Study:
- To evaluate the association between biologic therapies for psoriasis and the incidence of dementia.
- To investigate if specific biologic agents targeting inflammatory pathways impact dementia risk.
Main Methods:
- Retrospective cohort study of patients aged 65+ with psoriasis.
- Comparison of patients receiving biologic therapy post-systemic treatment versus systemic treatment alone.
- Propensity score matching used to create comparable groups (n=1766).
Main Results:
- Biologic therapy was associated with a 53% reduced risk of dementia (HR 0.47).
- Multivariate Cox model confirmed a reduced dementia risk (aHR 0.52) after adjusting for confounders.
- The association remained significant even after accounting for age and other factors.
Conclusions:
- Biologic therapies targeting tumor necrosis factor-alpha, interleukin-17, and interleukin-23 may reduce dementia risk.
- These findings suggest potential neuroprotective benefits of psoriasis biologics.
- Further research is warranted to confirm these neuroprotective effects in clinical practice.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
132
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
132
01:24T Cell Types and Functions
638
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
638
01:30Dementia
73
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
73
01:26Alzheimer's Disease: Overview
336
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
336
01:24Parkinson's Disease: Treatment
158
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
158
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
101
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
101